Major Estimate Revision • 10h
Consensus revenue estimates increase by 64% The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from US$15.0m to US$24.6m. Forecast losses expected to reduce from -US$0.998 to -US$0.801 per share. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target of US$6.00 unchanged from last update. Share price rose 3.3% to US$2.84 over the past week. Price Target Changed • Aug 07
Price target increased by 17% to US$6.71 Up from US$5.72, the current price target is an average from 7 analysts. New target price is 133% above last closing price of US$2.88. Stock is up 30% over the past year. The company is forecast to post a net loss per share of US$0.78 next year compared to a net loss per share of US$1.80 last year. Reported Earnings • Aug 06
Second quarter 2026 earnings: EPS and revenues exceed analyst expectations Second quarter 2026 results: US$0.15 loss per share (improved from US$0.63 loss in 2Q 2025). Revenue: US$11.9m (up 232% from 2Q 2025). Net loss: US$18.2m (loss narrowed 66% from 2Q 2025). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 45%. Revenue is expected to decline by 17% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 23%. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings. 공고 • Aug 05
Editas Medicine, Inc. Announces Board of Directors Changes Editas Medicine, Inc. announced the appointment of Patrick T. Ellinor, M.D., Ph.D., to its Board of Directors, effective August 6, 2026. The company also announced that Elliott Levy, M.D., will step down from the Board and his role as an independent director. Dr. Ellinor has dedicated his career to advancing the understanding of cardiovascular disease through human genetics. His research has helped identify novel therapeutic targets for cardiovascular disease and advance the translation of discoveries in human genetics toward potential new therapies. Throughout his career, he has combined pioneering research with clinical leadership and extensive collaborations across academia and industry to accelerate the development of innovative medicines for patients. Dr. Ellinor currently serves as the Executive Director of the Heart and Vascular Institute at Mass General Brigham, an Institute Member and Director of the Cardiovascular Disease Initiative at The Broad Institute of Harvard and MIT, and a Professor of Medicine at Harvard Medical School. He is also the Telemachus and Irene Demoulas Family Foundation Endowed Chair in Cardiology. As Executive Director of the Heart and Vascular Institute at Mass General Brigham, Dr. Ellinor leads one of the nation’s largest integrated cardiovascular organizations, bringing together clinicians, researchers, and staff across cardiology, cardiac surgery, vascular surgery, research, and education to advance heart and vascular care. At the Broad Institute, he directs the Cardiovascular Disease Initiative, leading multidisciplinary research and collaborations spanning human genetics, genomics, computational biology, artificial intelligence, and therapeutic discovery. His research has contributed to genetic analyses of atrial fibrillation and other cardiovascular diseases, helping shape the field’s understanding of cardiovascular genetics and informing the discovery of novel therapeutic approaches. Throughout his career, Dr. Ellinor has built multidisciplinary research programs and led collaborations across academia and industry to accelerate the translation of discoveries in human genetics into potential new medicines. He has also maintained a longstanding commitment to education and mentorship, training clinical fellows, postdoctoral researchers, and graduate students. Dr. Ellinor received his B.S. in biology from the University of Cincinnati and attended medical and graduate school at Stanford University, followed by medical internship and residency at Brigham and Women’s Hospital. He then completed fellowship training in cardiology and cardiac electrophysiology at Massachusetts General Hospital. New Risk • Jul 30
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$58k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 8.9% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (83% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$145m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Significant insider selling over the past 3 months (US$58k sold). New Risk • May 28
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 83% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 8.9% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (83% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$145m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). 
